Get the Stockscreener App
57.85
1.63%
-0.96
After Hours:
56.05
-1.80
-3.11%
Biomarin Pharmaceutical Inc stock is traded at $57.85, with a volume of 2.32M.
It is down -1.63% in the last 24 hours and up +5.24% over the past month.
BioMarin is a global biotechnology company focused on developing and commercializing therapies for rare genetic diseases. BioMarin specializes in enzyme replacement therapies, gene therapies, and other advanced treatments aimed at addressing complex genetic disorders. The company has eight approved therapies for conditions including achondroplasia, phenylketonuria (PKU), hemophilia, and mucopolysaccharidosis. BioMarin has an expanding, yet relatively early-stage, pipeline of treatments in development.
See More
Previous Close:
$58.81
Open:
$58.24
24h Volume:
2.32M
Relative Volume:
1.15
Market Cap:
$11.09B
Revenue:
$2.95B
Net Income/Loss:
$523.88M
P/E Ratio:
21.51
EPS:
2.69
Net Cash Flow:
$620.18M
1W Performance:
-3.20%
1M Performance:
+5.24%
6M Performance:
-8.70%
1Y Performance:
-31.40%
1-Day Range:
$57.36
$59.01
1-Week Range:
$57.36
$60.09
52-Week Range:
$52.93
$94.85
Biomarin Pharmaceutical Inc Stock (BMRN) Company Profile
Name
Biomarin Pharmaceutical Inc
Sector
Industry
Phone
(415) 506-6700
Address
105 DIGITAL DRIVE, NOVATO, CA
Compare BMRN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BMRN
Biomarin Pharmaceutical Inc
|
57.85 | 11.28B | 2.95B | 523.88M | 620.18M | 2.69 |
|
VRTX
Vertex Pharmaceuticals Inc
|
456.87 | 120.48B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
545.46 | 59.88B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
392.24 | 44.31B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
670.33 | 36.65B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
301.13 | 32.46B | 3.81B | -644.79M | -669.77M | -6.24 |
Biomarin Pharmaceutical Inc Stock (BMRN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-03-25 | Resumed | Morgan Stanley | Overweight |
| Feb-24-25 | Upgrade | Oppenheimer | Perform → Outperform |
| Nov-15-24 | Initiated | Wolfe Research | Outperform |
| Oct-30-24 | Downgrade | William Blair | Outperform → Mkt Perform |
| Oct-10-24 | Resumed | Raymond James | Outperform |
| Aug-20-24 | Upgrade | Bernstein | Mkt Perform → Outperform |
| May-17-24 | Downgrade | Robert W. Baird | Outperform → Neutral |
| May-14-24 | Initiated | Evercore ISI | Outperform |
| Nov-15-23 | Initiated | Wells Fargo | Overweight |
| Oct-23-23 | Upgrade | Bernstein | Underperform → Mkt Perform |
| Sep-28-23 | Initiated | Raymond James | Mkt Perform |
| Sep-18-23 | Initiated | UBS | Buy |
| Jul-27-23 | Initiated | Scotiabank | Sector Perform |
| Jul-05-23 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Jun-14-23 | Resumed | Credit Suisse | Outperform |
| Mar-21-23 | Initiated | Bernstein | Underperform |
| Feb-22-23 | Downgrade | Oppenheimer | Outperform → Perform |
| Feb-21-23 | Initiated | Citigroup | Neutral |
| Jan-30-23 | Initiated | BMO Capital Markets | Market Perform |
| Jan-18-23 | Initiated | Canaccord Genuity | Hold |
| Oct-31-22 | Upgrade | Oppenheimer | Perform → Outperform |
| Jul-13-22 | Initiated | Cantor Fitzgerald | Overweight |
| Jun-13-22 | Resumed | Wedbush | Neutral |
| Apr-25-22 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Nov-22-21 | Upgrade | William Blair | Mkt Perform → Outperform |
| Oct-07-21 | Resumed | Jefferies | Buy |
| Sep-09-21 | Upgrade | Stifel | Hold → Buy |
| Jun-04-21 | Resumed | Robert W. Baird | Outperform |
| Apr-26-21 | Resumed | Credit Suisse | Outperform |
| Mar-04-21 | Resumed | Guggenheim | Buy |
| Mar-01-21 | Upgrade | Evercore ISI | In-line → Outperform |
| Aug-20-20 | Downgrade | Citigroup | Buy → Neutral |
| Aug-20-20 | Downgrade | William Blair | Outperform → Mkt Perform |
| Aug-19-20 | Downgrade | Evercore ISI | Outperform → In-line |
| Aug-19-20 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Aug-19-20 | Downgrade | Stifel | Buy → Hold |
| Jul-08-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jul-06-20 | Reiterated | Citigroup | Buy |
| Jan-28-20 | Initiated | BMO Capital Markets | Market Perform |
| Jan-27-20 | Initiated | BMO Capital Markets | Market Perform |
| Jan-24-20 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Nov-27-19 | Upgrade | Barclays | Equal Weight → Overweight |
| Nov-12-19 | Initiated | SunTrust | Buy |
| Oct-17-19 | Resumed | BofA/Merrill | Buy |
| May-23-19 | Resumed | Citigroup | Buy |
| Apr-09-19 | Resumed | Raymond James | Outperform |
| Jan-02-19 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Dec-14-18 | Initiated | Wolfe Research | Outperform |
| Oct-01-18 | Initiated | Cantor Fitzgerald | Overweight |
| Aug-07-18 | Reiterated | Stifel | Buy |
| Aug-03-18 | Reiterated | Stifel | Buy |
View All
Biomarin Pharmaceutical Inc Stock (BMRN) Latest News
What is the risk reward ratio of investing in BioMarin Pharmaceutical Inc. stockMarket Forecast Report For Fast Growth - jammulinksnews.com
BioMarin Pharmaceutical Inc. Company’s Quarterly Earnings Growth: What the Numbers SayLow Risk High Return Opportunities Identified - metal.it
Trendlines Converge — Decision Point for BioMarin Pharmaceutical Inc.Watchlist for Low Risk High Return Stocks Updated - metal.it
PTC To Challenge BioMarin In PKU With Oral Sephience - insights.citeline.com
BioMarin Pharmaceutical Inc. Stock Performance After Earnings: Historical InsightsCommunity Verified Stock Suggestions Drive Volume - metal.it
BioMarin Pharmaceutical Inc. Recovery Likely Here’s What Data ShowsPattern Alert With ROI Driven Strategy Shared - metal.it
Earnings Chart Overlay Points to BioMarin Pharmaceutical Inc. UpsideWeekly Stock Opportunity Radar Scanner Activated - beatles.ru
US FDA approves PTC Therapeutics' metabolic disorder drug - Reuters
BioMarin Pharmaceutical (BMRN) Reports Next Week: Wall Street Expects Earnings Growth - Yahoo Finance
Should I hold or sell BioMarin Pharmaceutical Inc. stock in 2025Achieve rapid wealth accumulation through smart investing - jammulinksnews.com
What is BioMarin Pharmaceutical Inc. company’s growth strategyTrack top-performing stocks in real-time - jammulinksnews.com
Leerink Partners Maintains a Buy on BioMarin Pharmaceutical (BMRN), Retains a $105 PT - Insider Monkey
What makes BioMarin Pharmaceutical Inc. stock price move sharplyHigh Reward Swing Trades - metal.it
Why is BioMarin Pharmaceutical Inc. stock attracting strong analyst attentionBuild wealth with reliable stock picks - jammulinksnews.com
What are analysts’ price targets for BioMarin Pharmaceutical Inc. in the next 12 monthsTremendous return rates - jammulinksnews.com
What catalysts could drive BioMarin Pharmaceutical Inc. stock higher in 2025Unlock exclusive trading strategies for gains - jammulinksnews.com
When is BioMarin Pharmaceutical Inc. stock expected to show significant growthConsistently outstanding ROI - jammulinksnews.com
10 Most Profitable Biotech Stocks to Invest in Now - Insider Monkey
Is BioMarin Pharmaceutical Inc. a good long term investmentStrongest growth potential - PrintWeekIndia
What analysts say about BioMarin Pharmaceutical Inc. stockOutstanding growth strategies - PrintWeekIndia
Published on: 2025-07-25 23:58:58 - PrintWeekIndia
What risks could impact BioMarin Pharmaceutical Inc. stock performanceExceptional ROI - jammulinksnews.com
BioMarin’s BMN 349: A Promising Step in Genetic Lung Condition Treatment - TipRanks
Will BioMarin Pharmaceutical Inc. stock benefit from AI tech trendsFree Consultation - jammulinksnews.com
BioMarin to Host Second Quarter 2025 Financial Results Conference Call and Webcast on Monday, August 4, 2025, at 4:30pm ET - Eastern Progress
BioMarin: Less Likely M&A Target As New Rival For Best-Selling Drug Emerges (Rating Downgrade) - Seeking Alpha
BioMarin Pharmaceutical Inc. Stock Analysis and ForecastOutstanding growth strategies - Autocar Professional
What drives BioMarin Pharmaceutical Inc. stock priceAccelerated earnings growth - Autocar Professional
Investors Still Waiting For A Pull Back In BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) - simplywall.st
BioMarin Pharmaceutical Q2 2025 Earnings Call: CEO Alexander Hardy to Present Financial Results - Stock Titan
BioMarin Bets On Growth, But Competition Keeps Pressure On - Finimize
Biomarin Pharmaceutical Inc Stock (BMRN) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.43%
2.00%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):